Rationale and Design of “Can Very Low Dose Rivaroxaban (VLDR) in Addition to Dual Antiplatelet Therapy Improve Thrombotic Status in Acute Coronary Syndrome (VaLiDate-R)” Study

Journal of Thrombosis and Thrombolysis - Netherlands
doi 10.1007/s11239-019-02014-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Underutilisation of Dual Antiplatelet Therapy in Acute Coronary Syndrome

International Journal of Cardiology
Cardiovascular MedicineCardiology
2017English

Antiplatelet Therapy in Acute Coronary Syndrome

Continuing Cardiology Education
2017English

The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention

Rational Pharmacotherapy in Cardiology
Cardiovascular MedicinePharmacologyCardiology
2019English

Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome

Annals of Internal Medicine
Internal MedicineMedicine
2014English

Factors Associated With Platelet Reactivity During Dual Antiplatelet Therapy in Patients With Diabetes After Acute Coronary Syndrome

Scientific Reports
Multidisciplinary
2020English

Old and New Players in Oral Antiplatelet Therapy in Treatment of Acute Coronary Syndrome

Nepal Journal of Medical Sciences
1970English

Rivaroxaban in Patients With a Recent Acute Coronary Syndrome

Indian Heart Journal
Cardiovascular MedicineCardiology
2012English

Rationale and Role of High Loading Dose Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Pharmacology & Pharmacy
2012English

Is There a Rationale for Antiplatelet Therapy in Acute Heart Failure?

Circulation. Heart failure
MedicineCardiovascular MedicineCardiology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy